Special Diabetes Program Reauthorization Act of 2025
Summary
HB5461, the Special Diabetes Program Reauthorization Act of 2025, would extend federal funding for Special Diabetes Programs focused on Type I diabetes. The bill amends the Public Health Service Act to add a new funding authorization of $160 million for each fiscal year from 2026 through 2030, with the money remaining available until expended. In practical terms, it continues support for research, prevention, treatment, and related activities carried out under the Special Diabetes Programs.
The measure is a straightforward reauthorization and funding extension rather than a broader policy overhaul. It keeps the existing program structure in place while ensuring continued appropriations authority for five additional fiscal years. The bill was introduced in the House and referred to the Committee on Energy and Commerce, with no recorded amendments, committee votes, or floor action in the materials provided.
Impact
If enacted, the bill would amend section 330B(b)(2) of the Public Health Service Act to authorize an additional $160 million annually for fiscal years 2026 through 2030 for Special Diabetes Programs for Type I diabetes. This would extend federal support for diabetes-related research and services and maintain the legal basis for funding these programs beyond the current authorization period. The bill would primarily affect federal public health funding and the agencies, researchers, and patient-focused programs that rely on this authorization.
Sentiment
The available materials suggest generally positive and bipartisan support for the bill’s purpose, as reflected by the introduction from Ms. DeGette with Mr. Bilirakis and Mr. Ruiz as cosponsors. The bill’s title and text indicate a routine reauthorization of an established health program, and there is no recorded opposition, vote, or committee debate in the provided context. Overall, the sentiment appears favorable and noncontroversial.
Contention
No specific points of contention are identified in the provided record because there are no committee transcripts, amendments, or votes. If any concerns were to arise, they would likely center on federal spending levels, the duration of the authorization, or the effectiveness of the Special Diabetes Programs, but none of those issues are documented here. The bill appears to be a clean extension of existing funding rather than a contested policy change.